Soluble CD40 ligand induces expression of CD25 and CD23 in resting human tonsillar B lymphocytes
In this report, we describe the dose‐dependent increase in both CD25 and CD23 levels on resting human B cells in response to CD40 ligation, as mediated by soluble CD40 ligand (sCD40L) or anti‐CD40 antibody. In combination with interleukin (IL)‐4, sCD40L had limited additive effects on CD25 expressio...
Gespeichert in:
| Veröffentlicht in: | European journal of immunology 1996-05, Vol.26 (5), p.1069-1073 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1073 |
|---|---|
| container_issue | 5 |
| container_start_page | 1069 |
| container_title | European journal of immunology |
| container_volume | 26 |
| creator | Burlinson, Ellen L. Graber, Pierre Bonnefoy, Jean‐Yves Ozanne, Bradford W. Cushley, William |
| description | In this report, we describe the dose‐dependent increase in both CD25 and CD23 levels on resting human B cells in response to CD40 ligation, as mediated by soluble CD40 ligand (sCD40L) or anti‐CD40 antibody. In combination with interleukin (IL)‐4, sCD40L had limited additive effects on CD25 expression, but significantly enhanced CD23 expression on tonsillar B cells. Interferon‐γ (IFN‐γ) exerted no inhibitory effect upon increases in CD25 or CD23 driven by CD40 ligation with sCD40L or anti‐CD40 antibody. These data suggest that the induction of CD25 and CD23 genes by IL‐4 is mediated, at least in part, by an IFN‐γ‐sensitive component, whereas gene activation driven via CD40 ligation involves signaling pathways which are not sensitive to IFN‐γ. |
| doi_str_mv | 10.1002/eji.1830260517 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15644273</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15644273</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3717-33387344850d0b8b73ecdb069247367871c0d4c0938588b6eeb62e8e18d534543</originalsourceid><addsrcrecordid>eNqFkLtOw0AQRVcIFMKjpUPais5h1vt0CSFAUCQKoDZ-TJKNbG_wxgL_PRslAjqqGemeuRodQi4YjBhAfI0rO2KGQ6xAMn1AhkzGLBJMsEMyBGAiihMDx-TE-xUAJEomAzIwSmimkiF5f3FVl1dIx3cCaGUXWVNS25RdgZ7i17pF761rqJsHIpZ0G4eFB4aGbGObBV12ddbQjWu8raqspbe06uv10hX9Bv0ZOZpnlcfz_Twlb_eT1_FjNHt-mI5vZlHBNdMR59xoLoSRUEJucs2xKHNQSSw0V9poVkApCki4kcbkCjFXMRpkppRcSMFPydWud926jy58ltbWFxgeatB1PmVSCRFrHsDRDixa532L83Td2jpr-5RBulWaBqXpr9JwcLlv7vIayx987zDkyS7_tBX2_7Slk6fpn-5vGtt_sw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15644273</pqid></control><display><type>article</type><title>Soluble CD40 ligand induces expression of CD25 and CD23 in resting human tonsillar B lymphocytes</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Burlinson, Ellen L. ; Graber, Pierre ; Bonnefoy, Jean‐Yves ; Ozanne, Bradford W. ; Cushley, William</creator><creatorcontrib>Burlinson, Ellen L. ; Graber, Pierre ; Bonnefoy, Jean‐Yves ; Ozanne, Bradford W. ; Cushley, William</creatorcontrib><description>In this report, we describe the dose‐dependent increase in both CD25 and CD23 levels on resting human B cells in response to CD40 ligation, as mediated by soluble CD40 ligand (sCD40L) or anti‐CD40 antibody. In combination with interleukin (IL)‐4, sCD40L had limited additive effects on CD25 expression, but significantly enhanced CD23 expression on tonsillar B cells. Interferon‐γ (IFN‐γ) exerted no inhibitory effect upon increases in CD25 or CD23 driven by CD40 ligation with sCD40L or anti‐CD40 antibody. These data suggest that the induction of CD25 and CD23 genes by IL‐4 is mediated, at least in part, by an IFN‐γ‐sensitive component, whereas gene activation driven via CD40 ligation involves signaling pathways which are not sensitive to IFN‐γ.</description><identifier>ISSN: 0014-2980</identifier><identifier>EISSN: 1521-4141</identifier><identifier>DOI: 10.1002/eji.1830260517</identifier><identifier>PMID: 8647169</identifier><language>eng</language><publisher>Weinheim: WILEY‐VCH Verlag GmbH</publisher><subject>Antibodies, Monoclonal - pharmacology ; B lymphocytes ; B-Lymphocytes - drug effects ; B-Lymphocytes - immunology ; B-Lymphocytes - metabolism ; CD23 ; CD25 ; CD40 ; CD40 Antigens - immunology ; CD40 Ligand ; Drug Synergism ; Humans ; Interferon-gamma - pharmacology ; Interleukin-4 - pharmacology ; Interphase - drug effects ; Interphase - immunology ; Ligands ; Lymphocyte Count ; Membrane Glycoproteins - antagonists & inhibitors ; Membrane Glycoproteins - immunology ; Membrane Glycoproteins - pharmacology ; Palatine Tonsil - drug effects ; Palatine Tonsil - metabolism ; Receptors, IgE - antagonists & inhibitors ; Receptors, IgE - biosynthesis ; Receptors, IgE - drug effects ; Receptors, Interleukin-2 - antagonists & inhibitors ; Receptors, Interleukin-2 - biosynthesis ; Receptors, Interleukin-2 - drug effects ; Solubility</subject><ispartof>European journal of immunology, 1996-05, Vol.26 (5), p.1069-1073</ispartof><rights>Copyright © 1996 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3717-33387344850d0b8b73ecdb069247367871c0d4c0938588b6eeb62e8e18d534543</citedby><cites>FETCH-LOGICAL-c3717-33387344850d0b8b73ecdb069247367871c0d4c0938588b6eeb62e8e18d534543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Feji.1830260517$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Feji.1830260517$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8647169$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Burlinson, Ellen L.</creatorcontrib><creatorcontrib>Graber, Pierre</creatorcontrib><creatorcontrib>Bonnefoy, Jean‐Yves</creatorcontrib><creatorcontrib>Ozanne, Bradford W.</creatorcontrib><creatorcontrib>Cushley, William</creatorcontrib><title>Soluble CD40 ligand induces expression of CD25 and CD23 in resting human tonsillar B lymphocytes</title><title>European journal of immunology</title><addtitle>Eur J Immunol</addtitle><description>In this report, we describe the dose‐dependent increase in both CD25 and CD23 levels on resting human B cells in response to CD40 ligation, as mediated by soluble CD40 ligand (sCD40L) or anti‐CD40 antibody. In combination with interleukin (IL)‐4, sCD40L had limited additive effects on CD25 expression, but significantly enhanced CD23 expression on tonsillar B cells. Interferon‐γ (IFN‐γ) exerted no inhibitory effect upon increases in CD25 or CD23 driven by CD40 ligation with sCD40L or anti‐CD40 antibody. These data suggest that the induction of CD25 and CD23 genes by IL‐4 is mediated, at least in part, by an IFN‐γ‐sensitive component, whereas gene activation driven via CD40 ligation involves signaling pathways which are not sensitive to IFN‐γ.</description><subject>Antibodies, Monoclonal - pharmacology</subject><subject>B lymphocytes</subject><subject>B-Lymphocytes - drug effects</subject><subject>B-Lymphocytes - immunology</subject><subject>B-Lymphocytes - metabolism</subject><subject>CD23</subject><subject>CD25</subject><subject>CD40</subject><subject>CD40 Antigens - immunology</subject><subject>CD40 Ligand</subject><subject>Drug Synergism</subject><subject>Humans</subject><subject>Interferon-gamma - pharmacology</subject><subject>Interleukin-4 - pharmacology</subject><subject>Interphase - drug effects</subject><subject>Interphase - immunology</subject><subject>Ligands</subject><subject>Lymphocyte Count</subject><subject>Membrane Glycoproteins - antagonists & inhibitors</subject><subject>Membrane Glycoproteins - immunology</subject><subject>Membrane Glycoproteins - pharmacology</subject><subject>Palatine Tonsil - drug effects</subject><subject>Palatine Tonsil - metabolism</subject><subject>Receptors, IgE - antagonists & inhibitors</subject><subject>Receptors, IgE - biosynthesis</subject><subject>Receptors, IgE - drug effects</subject><subject>Receptors, Interleukin-2 - antagonists & inhibitors</subject><subject>Receptors, Interleukin-2 - biosynthesis</subject><subject>Receptors, Interleukin-2 - drug effects</subject><subject>Solubility</subject><issn>0014-2980</issn><issn>1521-4141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkLtOw0AQRVcIFMKjpUPais5h1vt0CSFAUCQKoDZ-TJKNbG_wxgL_PRslAjqqGemeuRodQi4YjBhAfI0rO2KGQ6xAMn1AhkzGLBJMsEMyBGAiihMDx-TE-xUAJEomAzIwSmimkiF5f3FVl1dIx3cCaGUXWVNS25RdgZ7i17pF761rqJsHIpZ0G4eFB4aGbGObBV12ddbQjWu8raqspbe06uv10hX9Bv0ZOZpnlcfz_Twlb_eT1_FjNHt-mI5vZlHBNdMR59xoLoSRUEJucs2xKHNQSSw0V9poVkApCki4kcbkCjFXMRpkppRcSMFPydWud926jy58ltbWFxgeatB1PmVSCRFrHsDRDixa532L83Td2jpr-5RBulWaBqXpr9JwcLlv7vIayx987zDkyS7_tBX2_7Slk6fpn-5vGtt_sw</recordid><startdate>199605</startdate><enddate>199605</enddate><creator>Burlinson, Ellen L.</creator><creator>Graber, Pierre</creator><creator>Bonnefoy, Jean‐Yves</creator><creator>Ozanne, Bradford W.</creator><creator>Cushley, William</creator><general>WILEY‐VCH Verlag GmbH</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>199605</creationdate><title>Soluble CD40 ligand induces expression of CD25 and CD23 in resting human tonsillar B lymphocytes</title><author>Burlinson, Ellen L. ; Graber, Pierre ; Bonnefoy, Jean‐Yves ; Ozanne, Bradford W. ; Cushley, William</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3717-33387344850d0b8b73ecdb069247367871c0d4c0938588b6eeb62e8e18d534543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Antibodies, Monoclonal - pharmacology</topic><topic>B lymphocytes</topic><topic>B-Lymphocytes - drug effects</topic><topic>B-Lymphocytes - immunology</topic><topic>B-Lymphocytes - metabolism</topic><topic>CD23</topic><topic>CD25</topic><topic>CD40</topic><topic>CD40 Antigens - immunology</topic><topic>CD40 Ligand</topic><topic>Drug Synergism</topic><topic>Humans</topic><topic>Interferon-gamma - pharmacology</topic><topic>Interleukin-4 - pharmacology</topic><topic>Interphase - drug effects</topic><topic>Interphase - immunology</topic><topic>Ligands</topic><topic>Lymphocyte Count</topic><topic>Membrane Glycoproteins - antagonists & inhibitors</topic><topic>Membrane Glycoproteins - immunology</topic><topic>Membrane Glycoproteins - pharmacology</topic><topic>Palatine Tonsil - drug effects</topic><topic>Palatine Tonsil - metabolism</topic><topic>Receptors, IgE - antagonists & inhibitors</topic><topic>Receptors, IgE - biosynthesis</topic><topic>Receptors, IgE - drug effects</topic><topic>Receptors, Interleukin-2 - antagonists & inhibitors</topic><topic>Receptors, Interleukin-2 - biosynthesis</topic><topic>Receptors, Interleukin-2 - drug effects</topic><topic>Solubility</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burlinson, Ellen L.</creatorcontrib><creatorcontrib>Graber, Pierre</creatorcontrib><creatorcontrib>Bonnefoy, Jean‐Yves</creatorcontrib><creatorcontrib>Ozanne, Bradford W.</creatorcontrib><creatorcontrib>Cushley, William</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>European journal of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burlinson, Ellen L.</au><au>Graber, Pierre</au><au>Bonnefoy, Jean‐Yves</au><au>Ozanne, Bradford W.</au><au>Cushley, William</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Soluble CD40 ligand induces expression of CD25 and CD23 in resting human tonsillar B lymphocytes</atitle><jtitle>European journal of immunology</jtitle><addtitle>Eur J Immunol</addtitle><date>1996-05</date><risdate>1996</risdate><volume>26</volume><issue>5</issue><spage>1069</spage><epage>1073</epage><pages>1069-1073</pages><issn>0014-2980</issn><eissn>1521-4141</eissn><abstract>In this report, we describe the dose‐dependent increase in both CD25 and CD23 levels on resting human B cells in response to CD40 ligation, as mediated by soluble CD40 ligand (sCD40L) or anti‐CD40 antibody. In combination with interleukin (IL)‐4, sCD40L had limited additive effects on CD25 expression, but significantly enhanced CD23 expression on tonsillar B cells. Interferon‐γ (IFN‐γ) exerted no inhibitory effect upon increases in CD25 or CD23 driven by CD40 ligation with sCD40L or anti‐CD40 antibody. These data suggest that the induction of CD25 and CD23 genes by IL‐4 is mediated, at least in part, by an IFN‐γ‐sensitive component, whereas gene activation driven via CD40 ligation involves signaling pathways which are not sensitive to IFN‐γ.</abstract><cop>Weinheim</cop><pub>WILEY‐VCH Verlag GmbH</pub><pmid>8647169</pmid><doi>10.1002/eji.1830260517</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2980 |
| ispartof | European journal of immunology, 1996-05, Vol.26 (5), p.1069-1073 |
| issn | 0014-2980 1521-4141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_15644273 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antibodies, Monoclonal - pharmacology B lymphocytes B-Lymphocytes - drug effects B-Lymphocytes - immunology B-Lymphocytes - metabolism CD23 CD25 CD40 CD40 Antigens - immunology CD40 Ligand Drug Synergism Humans Interferon-gamma - pharmacology Interleukin-4 - pharmacology Interphase - drug effects Interphase - immunology Ligands Lymphocyte Count Membrane Glycoproteins - antagonists & inhibitors Membrane Glycoproteins - immunology Membrane Glycoproteins - pharmacology Palatine Tonsil - drug effects Palatine Tonsil - metabolism Receptors, IgE - antagonists & inhibitors Receptors, IgE - biosynthesis Receptors, IgE - drug effects Receptors, Interleukin-2 - antagonists & inhibitors Receptors, Interleukin-2 - biosynthesis Receptors, Interleukin-2 - drug effects Solubility |
| title | Soluble CD40 ligand induces expression of CD25 and CD23 in resting human tonsillar B lymphocytes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T18%3A00%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Soluble%20CD40%20ligand%20induces%20expression%20of%20CD25%20and%20CD23%20in%20resting%20human%20tonsillar%20B%20lymphocytes&rft.jtitle=European%20journal%20of%20immunology&rft.au=Burlinson,%20Ellen%20L.&rft.date=1996-05&rft.volume=26&rft.issue=5&rft.spage=1069&rft.epage=1073&rft.pages=1069-1073&rft.issn=0014-2980&rft.eissn=1521-4141&rft_id=info:doi/10.1002/eji.1830260517&rft_dat=%3Cproquest_cross%3E15644273%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15644273&rft_id=info:pmid/8647169&rfr_iscdi=true |